Loading...
CAR-T cell therapeutics represent a major advance for patients with relapsed/refractory and high-risk myeloma, but longer-term outcomes have been uncertain. Now, at a median follow-up of 61 months, investigators report efficacy and safety in 97 heavily pretreated patients who received a single infusion of ciltacabtagene autoleucel (cilta-cel) in the CARTITUDE-1 trial.
Key findings:
One third of patients remain progression free.
Durable responses occurred in patients with aberrant TP53 and high-risk cytogenetics.
Twelve patients who achieved negative PET/CT also had undetectable minimal residual disease (MRD) after cilta-cel; all 12 remained negative on subsequent serial monitoring.
No new safety concerns were identified.